For Patients
For Physicians
Have you or a family member just had a heart attack?
If so, you or they may be able to take part in a new clinical study called dal-GenE-2 (also known as dal-302).
Learn more on becoming a patient
Are you a physician and want more information on the study?
Are you a physician and want more information on the study? If you are interested in becoming a clinical trial site, please click below.
Learn more as a physician

What is the dal-GenE-2 trial?

dal-GenE-2 is a clinical study to confirm the effect of dalcetrapib (the study drug) on reducing the risk of having a major cardiovascular event (fatal and non-fatal heart attack) in a population with a specific gene variant (AA genotype at variant rs 1967309 in the ADCY9 gene).

Who can take part?

  • Anyone who is aged 45 years or older
  • Lives in North America (United States or Canada)
  • Has been in hospital for an acute coronary syndrome (ACS) - e.g., a heart attack - within the past 3 months
  • Is medically stable on current treatment for this recent ACS

The dal-GenE-2 study is also known as the dal-302 clinical trial

Dalcetrapib is an investigational new drug (not approved yet by the regulatory health authorities) that has been tested in different large studies and demonstrated that it was well tolerated and had a potential benefit to reduce risk of major cardiovascular events (fatal and non-fatal heart attacks) in a population with a specific gene variant.

Become a patient of the clinical trial

Have you or a family member just had a heart attack (also known as a myocardial infarction)? If so, you or they may be able to take part in a new clinical study called dal-GenE-2 (also known as dal-302).

For Patients

Are you a physician and want more information on the study?

For clinical trials, researchers identify patients who fit a certain description, called eligibility criteria. dal-GenE-2 will be conducted in 150 sites across Canada and the USA.

For Physicians

dal-GenE-2 is a clinical study to confirm the effect of dalcetrapib (the study drug) on reducing the risk of having a major cardiovascular event (fatal and non-fatal heart attack) in a population with a specific gene variant (AA genotype at variant rs 1967309 in the ADCY9 gene).

Study sites / locations

dal-GenE-2 will be conducted in 150 sites across North America

© Copyright date. DalCor Pharmaceuticals. All rights reserved. Privacy Policy.
Website powered by: 2point0media Web Agency in Montreal

You cannot copy content of this page